Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. 1988

R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
Department of Psychiatry, University of Iowa College of Medicine, Iowa City.

In a multicenter placebo-controlled study, the safety, side effects, and patient acceptance of alprazolam for the treatment of panic disorder and agoraphobia were examined. A total of 525 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder were randomly assigned to receive alprazolam or placebo, which they took for eight weeks. The mean daily dose at the end of the study was 5.7 mg of alprazolam or 7.5 capsules of placebo daily. Potentially serious reactions to alprazolam occurred in ten of 263 subjects who received the drug. These included acute intoxication (three), hepatitis (two), mania (two), amnesia (one), aggressive behavior (one), and depression (one). Treatment-related side effects that were worse in patients taking alprazolam than in those taking placebo included sedation, fatigue, ataxia, slurred speech, and amnesia. Sedation was the most frequent but tended to subside with dose reduction or continued administration of the drug. Patient acceptance of alprazolam, as measured by the rate of completion for study participants, was high. Eighty-four percent of patients receiving active drug completed the study compared with 50% receiving placebo.

UI MeSH Term Description Entries
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D010200 Panic A state of extreme acute, intense anxiety and unreasoning fear accompanied by disorganization of personality function. Panics
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D010352 Patient Dropouts Discontinuance of care received by patient(s) due to reasons other than full recovery from the disease. Dropout, Patient,Dropouts, Patient,Patient Dropout
D010698 Phobic Disorders Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable. Claustrophobia,Neuroses, Phobic,Phobia, School,Phobias,Phobic Neuroses,Scolionophobia,Disorder, Phobic,Phobia,Phobic Disorder,School Phobia
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D005221 Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. Lassitude
D005239 Fear The affective response to an actual current external danger which subsides with the elimination of the threatening condition. Threat Cues,Threat Sensitivity,Cue, Threat,Fears,Sensitivity, Threat,Threat Cue,Threat Sensitivities

Related Publications

R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
May 1988, Archives of general psychiatry,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
July 1994, The British journal of psychiatry : the journal of mental science,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
October 1984, Texas medicine,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
February 1994, The Journal of nervous and mental disease,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
November 1992, The American journal of psychiatry,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
May 1994, The British journal of psychiatry : the journal of mental science,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
February 1989, Journal of clinical psychopharmacology,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
January 1986, Psychopharmacology bulletin,
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
January 1996, Journal of psychopharmacology (Oxford, England),
R Noyes, and R L DuPont, and J C Pecknold, and A Rifkin, and R T Rubin, and R P Swinson, and J C Ballenger, and G D Burrows
January 1997, Psychotherapy and psychosomatics,
Copied contents to your clipboard!